Deep knowledge on
small-molecule drugs and
the 90,000 global patents
covering them

Flexible Flat-Rate Plans

Flat-rate pricing for predictable budgeting

Short-term plans for project- or client-based billing

► Plans and Pricing

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: nesiritide recombinant

« Back to Dashboard
Nesiritide recombinant is the generic ingredient in one branded drug marketed by Scios Llc and is included in one NDA. Additional information is available in the individual branded drug profile pages.

There are two drug master file entries for nesiritide recombinant. One supplier is listed for this compound.

Summary for Generic Name: nesiritide recombinant

Drug Master File Entries: see list2
Suppliers / Packaging: see list1

Pharmacology for Ingredient: nesiritide recombinant

Clinical Trials for: nesiritide recombinant

Natriuretic Peptide System as Therapy in Human Preclinical Left Ventricle Dysfunction
Status: Completed Condition: Congestive Heart Failure

Natrecor for Pulmonary Hypertension in Lung Transplants
Status: Completed Condition: Pulmonary Hypertension

Use of Nesiritide in the Management of Acute Diastolic Heart Failure
Status: Terminated Condition: Heart Failure; Cardiovascular Disease; Acute Heart Failure; Diastolic Heart Failure; Congestive Heart Failure; Heart Disease

Effects of Perioperative Nesiritide or Milrinone Infusion on Recovery From Fontan Surgery
Status: Terminated Condition: Heart Defects, Congenital

Nesiritide and Renal Function After the Total Artificial Heart
Status: Terminated Condition: Congestive Heart Failure; Cardiorenal Syndrome

Double Blind Randomized Placebo Controlled Trial of Natrecor in Acute Decompensated Heart Failure With Normal EF
Status: Withdrawn Condition: Heart Failure, Congestive; Dyspnea; Pulmonary Edema

Nesiritide Use Following Cardiac Surgery in Infants
Status: Terminated Condition: Heart Defects, Congenital; Cardiopulmonary Bypass

Natrecor in Pulmonary Hypertension
Status: Terminated Condition: Pulmonary Hypertension; Cancer; Lung Disease; Cardiothoracic Surgery

Nesiritide Therapy to Preserve Function of the Left Ventricle After Myocardial Infarction
Status: Completed Condition: Acute Myocardial Infarction

Nesiritide Infusion for the Treatment of Decompensated Heart Failure and Renal Dysfunction
Status: Completed Condition: Congestive Heart Failure; Renal Insufficiency

Courtesy of
See more clinical trials for this drug
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Scios Llc
nesiritide recombinant
FOR SOLUTION;INTRAVENOUS020920-001Aug 10, 2001RXYes<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a trial or see the database preview and plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn